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Summary
Objective: Adult articular cartilage shows a limited intrinsic repair response to traumatic injury. To regenerate damaged cartilage, cell-assisted
repair is thus viewed as a promising therapy, despite being limited by the lack of a suitable technique to deliver and retain chondrogenic cells
at the defect site.
Design: We have developed a cytocompatible chitosan solution that is space-ﬁlling, gels within minutes, and adheres to cartilage and bone in
situ. This unique combination of properties suggested signiﬁcant potential for its use as an arthroscopically injectable vehicle for cell-assisted
cartilage repair. The primary goal of this study was to assess the ability of this polymer system, when loaded with primary articular
chondrocytes, to support cartilage formation in vitro and in vivo. The chitosan gel was cultured in vitro, with and without chondrocytes, as well
as injected subcutaneously in nude mice to form subcutaneous dorsal implants. In vitro and in vivo constructs were collectively analyzed
histologically, for chondrocyte mRNA and protein expression, for biochemical levels of glycosaminoglycan, collagen, and DNA, and for
mechanical properties.
Results: Resulting tissue constructs revealed histochemical, biochemical and mechanical properties comparable to those observed in vitro for
primary chondrocytes cultured in 2% agarose. Moreover, the gel was retained after injection into a surgically prepared, rabbit full-thickness
chondral defect after 1 day in vivo, and in rabbit osteochondral defects, up to 1 week.
Conclusions: The in situ-gelling chitosan solution described here can support in vitro and in vivo accumulation of cartilage matrix by primary
chondrocytes, while persisting in osteochondral defects at least 1 week in vivo.
ª 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.





Developments in therapeutic strategies for cartilage repair
have increasingly focused on the promising technology of
cell-assisted repair (reviewed in1,2), proposing to use
autologous chondrocytes or other cell types to regenerate
articular cartilage in situ. The method of cell implantation
within the articular joint poses special challenges, including
strong shear forces and mechanical loads, a ﬂuidic envi-
ronment, and a graft site composed of stiff, irregular, and
often bleeding surfaces not easily amenable to surgical
attachment of tissue ﬂaps or insertion of biomaterials.
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Received 19 May 2004; revision accepted 11 December 2004.31Moreover, biomaterials to be used as cell-delivery vehicles
must also meet stringent biocompatibility requirements in
that the material should be non-toxic, non-immunogenic,
and biodegrade without generating toxic by-products or
debris that could subsequently injure the joint. The bio-
material must either integrate in a mechanically and
physiologically harmonious manner with the repair tissue,
or degrade without leaving gaps or ﬁssures in the tissue.
Thus, one function of a biomaterial acting as a cell carrier for
cartilage repair is to serve as a temporary scaffolding that
permits the accumulation of extracellular matrix by delivered
cells, while leading to congruent attachment with the
perimeter of the cartilage defect and the subchondral bone.
In Autologous Cell Implantation (ACI), a currently prac-
ticed cell-based therapy to repair cartilage defects, autolo-
gous chondrocytes are recovered from the patient but are
considered too sparse for direct re-implantation3. To over-
come cell scarcity, chondrocytes are ampliﬁed in tissue
culture prior to re-implantation3,4. After one in vitro passage
(two cell doublings), chondrocytes can still form some
hyaline cartilage as a nude mouse implant5e7. However,8
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three to four population doublings for human ACI therapy3.
After three to four doublings, chondrocytes can no longer
produce cartilage matrix in the nude mouse implant model
using canine8, pig5, or human chondrocytes7. Therefore, in
tissue engineered constructs, the greatest biochemical
accumulation of cartilage matrix has been typically demon-
strated using primary chondrocytes.
A wide array of cytocompatible matrices or hydrogel
carriers have been seeded with articular chondrocytes in
order to regenerate cartilage matrix in vitro, including
scaffoldsmade of proteins (collagen, ﬁbrin), polysaccharides
(agarose, alginate, hyaluronic acid, chitosan), and polymers
(polyethylene glycol, poly-lactic acid) (reviewed in2). A
quantitative in vitro accumulation of cartilage matrix has
been demonstrated biochemically for chondrocytes cultured
in collagen9,10, agarose11, poly-glycolic acid12, alginate13,
ﬁbrin glue14, polyethylene glycol dimethacrylate15, and self-
assembling peptides16. Most of these matrices also support
neocartilage matrix deposition in vivo when placed as
implants into nude mice, and include poly-glycolic acid17,
alginate18,19, ﬁbrin glue5, and polyethylene oxide20e22.
Since primary chondrocytes appear to retain function and
phenotype in a multitude of cell carriers in vitro and in vivo,
a major obstacle in cell-assisted cartilage repair therapies
does not appear to be the generation of a chondrocyte-
compatible matrix, but rather the delivery and retention of
the cell-delivery vehicle within an articular defect. Although
semi-solid or solid matrices may reside in speciﬁcally
tailored animal defects, by press-ﬁtting23e26, suturing or
tacking27e29, or by using biologic or synthetic glues25,28,30,
such pre-formed implants cannot be designed to adequately
ﬁt the precise shape and form of a naturally occurring
defect, and typically lead to repair tissue with poor
attachment and poor integration29,31. By another approach,
cells have been delivered underneath a periosteal patch
sutured over the defect3,4,6, with resulting damage to the
cartilage defect margins29, and frequent failure due to dela-
mination of the ﬂap32. In summary, the above-mentioned
techniques suffer from potential loss of the transplanted
cells, attributable to a lack of implant adhesion to the defect,
poor ﬁtting of the delivery vehicle, or instability of the
implant, sutures, or glue.
Cell delivery to articular defects is thus viewed as
a promising therapy, despite being limited by an absence
of suitable techniques to deliver and retain chondrogenic
cells at the defect site. We have recently described
a potential solution to this problem using a chitosan-based
cell-delivery vehicle for articular cartilage repair that can
sustain chondrocyte viability during gelation and subse-
quent cell culture33e35. Chitosan has unique tissue-adhe-
sive properties due to its polycationic nature. The chitosan
cationic charge is predicted to be maintained36 at the
degree of deacetylation (DDA) and wpH 6.8 of our gel
carrier. When implanted in immunocompetent animals,
chitosan is biocompatible and biodegradable, with thus far
no indication of immunogenicity37 unless injected repeat-
edly with adjuvants and co-immunogens38. The chitosan-
based vehicle described here, for example, can be injected
as a viscous liquid, and upon solidiﬁcation, adheres to bone
and to cartilage. In the present study we have tested two
hypotheses: 1) that this chitosan gel can support the in vitro
and in vivo accumulation of mechanically stable cartilage
matrix produced by viable primary chondrocytes, and 2) that
this chitosan gel can adhere to cartilage and bone and
persist in situ for at least 1 week within different types of
joint defects in living animals.Materials and methods
INJECTABLE HYDROGEL-FORMING CHITOSAN SOLUTIONS
Chitosan was obtained either from BioSyntech (Laval,
QC, Canada), with a 90% DDA, free base form, average
molecular weight 216 kDa by GPC before autoclave, or
from Pronova (Oslo, Norway, Product No UP213 84% DDA,
16% HCl, 1% solution viscosity 143 mPa-s). BioSyntech
chitosan was dissolved in 88 mM HCl (Sigma, Tissue
Culture grade) at 1.8% (w/v) and autoclave sterilized.
Protasan UP213 powder was sterilized by exposure to UV
light for 2 h in a cell culture laminar ﬂow hood, and then
dissolved in sterile water at 1.7% (w/v) chitosan (Pronova
UP213, batch No. 607-783-02, taking into account HCl
content and loss on drying). These chitosaneHCl solutions
were individually mixed with concentrated stock solutions of
ﬁlter-sterilized disodium b-glycerol phosphate (GP, Sigma,
Tissue Culture grade, St. Louis, MO), and glucosamine
(Sigma, Tissue Culture grade), to yield a liquid chitosane
GPeglucosamine solution with 1.5% (Pronova) or 1.6%
(BioSyntech) chitosan, 108 mM disodium b-glycerol phos-
phate, 18 mM glucosamine, ﬁnal pH 6.8 (Pronova chitosan)
or pH 6.7 (BioSyntech chitosan). Chitosan gels were formed
by mixing 10 mL chitosaneGPeglucosamine solution with
2.5 mL of a cross-linking solution consisting of 2.5% (w/v in
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) ﬁlter-steril-
ized hydroxyethyl cellulose (Fluka, Ulm, Switzerland,
medium viscosity), and incubating at 37(C.
CHONDROCYTE ISOLATION, ENCAPSULATION, HYDROGEL
CULTURE INJECTION IN NUDE MICE
Primary calf chondrocytes were isolated by enzymatic
digestion of femoral-patellar groove cartilage of two, 2-week
post-natal calf knees within 6 h of sacriﬁce, as described11.
A pellet containing 130 million freshly isolated primary
chondrocytes (w0.75 ml packed volume) was resuspended
with 2 ml ﬁltered hydroxyethyl cellulose (25 mg/ml) and
mixed with 10.5 ml of 4(C chitosaneGPeglucosamine to
generate a solution of 10 million cells/ml which was poured
into 100 mm culture dishes and permitted to gel for 20 min
in a humidiﬁed, 37(C, 5% CO2 incubator followed by four,
20-min washes with DMEM. Chondrocytes were also cast
in 100 mm culture dishes at the same cell density in a 2%,
low-melting point agarose gel (SeaPlaque, FMC Bioprod-
ucts, Rockland, MA) according to Buschmann et al.11.
Control gels (chitosan and agarose) were cast without cells.
A biopsy punch was used to core 6-mm-diameter and
1.0 mm (chitosan) to 1.5 mm (agarose) thick discs from the
gel slabs. Discs were cultured in individual wells of 48-well
plates on top of washed, sterile 1000 mm nylon mesh grids
(Spectrum, Laguna Hills, CA), in 0.5e1.0 ml of complete
media [DMEM Sigma D5648; non-essential amino acids
Sigma, M2025; 0.4 mM proline Sigma, P4655; an additional
2 mM glutamine Sigma, G5763; 100 U/ml PenStrep Sigma
P0781; 10% Fetal Bovine Serum Sigma, and 50 mg/ml fresh
ascorbic acid Sigma, 134-03-2], replaced daily. Gel
constructs without cells were carried through identical
culture conditions as constructs with cells, including daily
fresh media changes. Culture dishes were shaken slowly
on an orbital platform in humidiﬁed 5% CO2, at 37(C. Cell
viability was determined using a calcein AM/ethidium-
homodimer-1 ﬂuorescent assay39.
NUDE MOUSE IMPLANTS
All procedures and protocols were approved by an
Institutional Animal Care and Use Committee (University
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million freshly isolated primary chondrocytes was resus-
pended with 1 ml ﬁltered hydroxyethyl cellulose (25 mg/ml)
and mixed with 5.0 ml of 4(C chitosaneGPeglucosamine
to generate a solution of 10 million cells/ml (3 week
implants) or 20 million cells/ml (7 or 9 week implants) which
was injected within 5 min of mixing. A 1 cc syringe and 26 g
1⁄2 inch needle was used to generate one 400 ml implant
with (nZ 2) or without cells (nZ 2) in the subcutaneous
dorsum of nude mice (25 g male CD1-Crl nu/nu, Charles
River, St Constant, QC) and allowed to develop for 3
weeks. In other nude mice, four, 100 ml implants were
injected in the four corners of the mouse dorsum either with
(nZ 5) or without cells (nZ 5) and allowed to develop for 7
or 9 weeks. Individual implants were recovered, dissected
from the capsule, and divided into portions that were either
ﬁxed, or frozen in liquid nitrogen, or cored with a 3 mm
biopsy punch for multiple analyses (histology, biochemistry,
RNAse protection, mechanical).
DETERMINATION OF COLLAGEN, GLYCOSAMINOGLYCAN,
AND DNA CONTENT
Individual 40e60 mg cultured discs, or 5e25 mg implant
samples, or fresh bovine articular cartilage explants were
frozen in liquid nitrogen, and stored at 80(C. Samples
were either extracted in guanidine salts [4 M guanidine HCl/
50 mM Tris pH 7.2 (GuCl), followed by 4 M guanidine
isothiocyanate/50 mM Tris pH 7.2 (GITC)], as previously
described35, or digested in 1 ml papain at pH 7.5 in
a manner similar to Kim et al.40. Total collagen content
was determined by hydroxyproline assay41 (conversion
factor of 7.6 mg collagen/mg hydroxyproline). GuCl extracts
and papain digests were submitted directly to the DMMB
assay to determine glycosaminoglycan (GAG) content, and
to the Hoechst 33258 DNA assay to estimate cell density35
(conversion factor of 7.7 pg DNA/cell40).
RNA ANALYSIS BY RNASE PROTECTION ASSAY
4 M GuCl/50 mM Tris pH 7.2 and 4 M GITC/50 mM Tris
pH 7.2 extracts were combined in equal proportions and
20 ml was submitted to direct mRNAse protection assay with
a commercial kit (Ambion, Austin, TX) using bovine-speciﬁc
RNAse protection probes for collagen type II, aggrecan, and
glyceraldehyde phosphate dehydrogenase (GAPDH), as
described previously35. Bovine tendon and kidney guani-
dine extracts were used as controls.
PROTEIN ANALYSIS BY WESTERN BLOTTING
Combined GuCl/GITC extracts were precipitated with ﬁve
volumes ethanol, and submitted to 7.5% acrylamide, SDS-
PAGE followed by parallel Western blot analyses using
monoclonal anti-vimentin V9 (Sigma, 1:5000 dilution),
monoclonal anti-Proliferating Cell Nuclear Antigen (anti-
PCNA) (Sigma, 1:2000), polyclonal anti-C-propeptide of
type II collagen (CP2) (R160, gift of R. Poole, Shriners
Hospital, Montreal, Canada, 1:10,000), monoclonal anti-link
protein 9/30/8-A-4 supernatant (Developmental Studies
Hybridoma Bank, Iowa City, IA, 1:20), followed by perox-
idase-conjugated secondary antibodies including anti-rabbit
(Sigma, 1:2000), and anti-mouse IgG (Vector Labs,
Burlington, ON, 1:2000) and chemiluminescence (Roche,
Amersham: link, vimentin, CP2) or (Pharmacia-Amersham,
ECL plus: PCNA). Complete protein transfer was veriﬁed bypost-staining of acrylamide gels with Coomasie Blue, and
Ponceau S was used to stain transferred molecular weight
markers.
HISTOLOGY
Cultured discs and freshly isolated implants were ﬁxed in
4% paraformaldehyde and 1% glutaraldehyde in 100 mM
sodium cacodylate buffer, at pH 7.2. For histological
assessment, samples were dehydrated and embedded in
LR-White acrylic resin (EM Sciences, Ft Washington, PA),
and semithin (1 mm) sections were cut on an ultramicrotome
and stained with toluidine blue (Fisher, Montreal, QC). For
immunohistochemistry, 5-mm-thick parafﬁn sections of
samples ﬁxed as above but without glutaraldehyde were
stained for aggrecan and link protein (polyclonal antisera
R110 or R295, respectively, gifts of A. Robin Poole,
Shriner’s Hospital, Montreal, QC, Canada). Aggrecan and
link protein antibodies were diluted at 1:100 and 1:200,
respectively, with 5% normal goat serum containing 0.2%
bovine serum albumin in Tris-buffered saline with Tween-20
(TBST; 50 mM TriseHCl, 150 mM NaCl, and 0.01% Tween-
20; pH 7.6). Sections were washed several times for 20 min
with TBST buffer, and then incubated with secondary
antibody (biotinylated goat anti-rabbit IgG; Caltag Labora-
tories, Burlingame, CA) diluted 1:200 with 0.2% bovine
serum albumin in TBST for 45 min at room temperature.
After additional washing with TBST, sections were further
treated with the Vectastain ABC-AP kit (Vector Laborato-
ries, Burlingame, CA) for 45 min at room temperature. Color
development was achieved with an 8-min treatment of Fast
Red TR/Naphthol AS-MX phosphate (Sigma) containing
1 mM Levamisole as an inhibitor of endogenous alkaline
phosphatase. After washing with distilled water, sections
were counterstained with methyl green for 2e5 min,
washed with distilled water and mounted under coverslips
using Kaiser’s glycerol jelly. Negative controls consisted of
the same treatment with the omission of the primary
antibody in the ﬁrst incubation.
BIOMECHANICAL PROPERTIES
Biomechanical properties of 3-mm- to 6-mm-diameter
discs were assessed via stress-relaxation tests in uniaxial,
unconﬁned compression using the Mach-1 micromechan-
ical testing system (BioSyntech, Laval, QC). Sample
diameter and thickness were determined using a microme-
ter. For gels cultured in vitro, two successive compression
ramps each with an amplitude corresponding to 10% of the
sample thickness were applied at a strain rate of 1%/s. For
all samples, equilibrium was estimated when the load
changed by less than 0.05 g/min. Chitosan in vivo implants
were submitted to a sequence of compression ramps of
2.5% of the sample thickness, at a strain rate of 0.25%/s.
Stress relaxation curves from the second ramp (10e20%
strain) of in vitro discs and the eighth ramp of the in vivo
implants (17.5e20% strain) were ﬁt to a ﬁbril reinforced
poroelastic model42 to obtain the compressive equilibrium
modulus (Em), tensile ﬁbril modulus (Ef) and hydraulic
permeability (k).
RABBIT FEMOROPATELLAR ARTICULAR DEFECTS
New Zealand White rabbits (nZ 6), 4e7 months old
(Charles River), were anesthetized by intramuscular
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isoﬂurane gas anesthesia. A medial parapatellar incision
exposed the joint, followed by joint capsule incision, and
patellar displacement. Exposed cartilage was irrigated with
Phosphate Buffered Saline (PBS). All animals received
bilateral arthrotomies to generate articular cartilage defects
on the patellar (nZ 1) or trochlear surfaces (nZ 5). One
animal received a full thickness (w0.3 mm deep) 4! 3 mm
chondral-only defect on the patellar surface of the left knee,
and a 3 mm deep osteochondral patellar defect in the right
knee and was allowed to heal for 1 day. Another animal
received chondral-only defects on left and right trochlear
surfaces with a microsurgical knife and was allowed to heal
for 1 day. In other animals (nZ 4), 3e5 mm deep bilateral
osteochondral defects were created in the trochlea by
removing the cartilage with a scalpel, then using a hand-held
high-speed drill and a 3 mm diameter drill bit with constant
4(C PBS irrigation to avoid thermal necrosis. Sterile liquid
chitosan gel without cells was loaded into both patellar
defects, or into one of the trochlear defects using a 1 cc
syringe and 20 g 1 inch needle to assess gel retention and
residency. In contrast with one injection in chondral-only
defects, liquid chitosan implant was re-injected a second or
third time into all four trochlear osteochondral defects before
defect hemostasis was observed. In situ gelation and the
arrest of bleeding occurred after a 5e10 min delay, after
which the patella was replaced and the capsule, muscle,
and skin were sequentially closed with 5-0 black braided silk
(Harvard Apparatus, Holliston, MA). Bilateral osteochondral
trochlear defects were allowed to heal for 1 day (nZ 1) or 1
week (nZ 3).
STATISTICAL ANALYSES
Quantitative biochemical (cell density, GAG concentra-
tion, collagen concentration) and biomechanical (Em, Ef, k)
outcomes were taken as dependent variables while scaffold
type (chitosan vs agarose) and day of culture were
independent variables (predictors). Multivariate analysis of
variance (MANOVA) using the GLM routines of Statistica
(Statsoft, Tulsa, OK) was used to assess the signiﬁcance
(P! 0.05) of the main effects (scaffold, day of culture) with
and without their interaction on dependent outcomes.
Contrast analysis for planned comparisons was then used




During a 3-week culture period in vitro, primary calf
chondrocytes produced comparable amounts of de novo
cartilage matrix in the chitosan and agarose gels, as
assessed by histological, molecular, and biochemical
criteria. Chondrocytes remained O90% viable in the solid
chitosan matrix immediately post-casting [Fig. 1(A)], and
throughout the 21-day, in vitro culture period [Fig. 1(B)].
Cells cultured in chitosan or agarose accumulated pericel-
lular sulfated GAG-containing matrix, as measured by
toluidine blue staining [Fig. 1(D,G)], in addition to pericellular
aggrecan (not shown) and pericellular link protein [Fig. 1(E)],
aggrecan mRNA [Fig. 2(B)], and extracted link protein
expression [Fig. 2(A)]. Total GAG concentration was lower
(P! 0.05) in chitosan (11.3 mg/mgat day 20) than in agarose
(15.6 mg/mg at day 20) while collagen concentrations weresimilar (Table I). No evidence of mineralization was seen by
von Kossa staining (data not shown). Chitosan scaffold was
still present after 21 days in culture [Fig. 1(D), open arrow].
The histological appearance of chitosan gel cultured from 1
to 14 days without cells was similar to that of chitosan gel
with cells at day 1 [Fig. 1(C), open arrow], indicating that the
gel did not biodegrade during 3 weeks in culture.
Chondrocytes in chitosan cultures or in implants produced
type II collagen, as reﬂected by C-propeptide II expression
[Fig. 2(A)], and abundant type II mRNA expression
[Fig. 2(B)]. Of note, calf chondrocytes cultured in chitosan
expressed only one CP2 isoform, as did fresh adult articular
cartilage explants, whereas calf chondrocytes in agarose
and calf explants expressed two CP2 isoforms (Fig. 2).
Type I collagen mRNA expression was detected by
Reverse Transcriptase-Polymerase Chain Reaction in both
agarose and chitosan gels at 21 days (data not shown).
Cells were observed to divide during the 3-week cultures as
determined by quantiﬁcation of absolute DNA content
(Table I). Cell density in chitosan cultures doubled at 14
days and then tapered off to a level that was signiﬁcantly
higher (P! 0.05) relative to agarose cultures where cell
density linearly increased by about half over 3 weeks. As
the hydrogel disc wet mass did not decrease signiﬁcantly
during the culture (Table I), the apparent increase in DNA
content was not caused by gel shrinkage, but may have
been partly due to a greater proliferation of cells that had
a ﬁbroblast shape on the surface of the chitosan discs
[Fig. 1(G,H)]. Chondrocytes cultured in chitosan or agarose
expressed PCNA, a cell cycle-associated protein [Fig. 2(A)].
PCNA was detected in 2-week calf articular cartilage, but
not in adult cartilage [Fig. 2(A)].
After 3 weeks in culture, a cell-dependent increase in
stiffness and decrease in hydraulic permeability (or pore
size) was observed for both chitosan and agarose discs
(Table I), which could be attributed to the accumulation of
GAG and collagen in the hydrogel pore spaces. Statistical
analysis showed signiﬁcant (P! 0.05) time- and scaffold-
dependent changes for all mechanical properties of in vitro
samples. Although the ﬁnal mechanical properties were
superior for cells grown in agarose compared to chitosan
(Table I), it must be noted that the initial 2% agarose
hydrogel was much stiffer (w5!) and less permeable
(w30!) than 1.3% chitosan gel (Table I). By comparison,
the fold-increase in mechanical properties over time was
always higher for chitosan, compared to agarose. For
instance, during 15 days in culture, the equilibrium
modulus of gels with chondrocytes increased by 9.2-fold
for chitosan (days 4e19), and 4.5-fold for agarose (days
5e20, Table I).
NUDE MOUSE IMPLANTS
Chondrocytes were encapsulated in liquid chitosan/
hydroxyethyl cellulose and injected subcutaneously in ﬁve
different nude mice, where implants were allowed to develop
for 3, 6, or 9 weeks in vivo (Fig. 3, Table I). Additional mice
received chitosan implants without cells. Solely the implants
with chondrocytes acquired a pearly white appearance of
hyaline cartilage, inside of which chondrocytes were
surrounded by a variable ring of pericellular GAG (Fig. 3).
A ﬁbrous capsule containing ﬁbroblasts, neutrophils and
blood vessels formed around all implants. Murine neutro-
phils, blood vessels, and capsular ﬁbroblasts were seen to
grow into the margins of implants with no cells [Fig. 3(G)],
while implants with chondrocytes showed reduced cellular
322 C. D. Hoemann et al.: Chitosan-based cell-delivery vehicleFig. 1. Histology of chondrocytes cultured in chitosan- (A, B, C, D, E, H) or agarose- (F, G, I) based hydrogels. Viability of chondrocytes freshly
encapsulated (A) and cultured for 20 days (B) was assessed with ﬂuorescent calcein AM (green live cells) and ethidium homodimer 1 (red
nuclei, dead cells). Toluidine blue-stained, LR White semithin sections are from day 0, immediately post-casting (C, F), and from day 20 of
culture (D, G) showing cell nuclei (arrows), GAG-rich extracellular matrix (arrowheads), and chitosan (open arrow). Immunohistochemistry with
anti-link protein antibody shows accumulation of pericellular link protein, an abundant cartilage extracellular matrix protein (E). Fibroblastic
cells grew in a variable layer on the surface of in vitro constructs (H, I). Scale barsZ 50 mm.
323Osteoarthritis and Cartilage Vol. 13, No. 4Fig. 2. Protein and mRNA expression patterns of primary chondrocytes in chitosan- or agarose-based hydrogels developed in vitro, as well as
two distinct in vivo nude mouse subcutaneous implants of chitosan gel loaded with chondrocytes (chon; two distinct implants at day 48 or 63,
shown in Fig. 3 and Table I). Negative controls include chitosan gel cultured without cells (NC ), in vivo nude mouse implants of chitosan gel
without chondrocytes (NC; two distinct implants at day 63), or bovine kidney (Kid ). Positive controls include extracts analyzed in parallel from
a similar wet mass of calf or adult bovine articular cartilage. A) Western blot analysis of duplicate samples from in vitro cultures collected at
days 0, 14, and 20 and individual in vivo implants from days 48 and 63. Results show the production of cartilage matrix proteins (collagen type
2 C-propeptide, CP2; link protein, Link) as well as a marker for cell proliferation (PCNA) in both chondrocyte-hydrogel systems. B) RNAse
protection analysis of the same samples in A showing continued expression of mRNAs characteristic of the chondrocyte phenotype
(Aggrecan, Collagen II) in both in vitro and in vivo systems. GAPDH mRNA was used as a control for the number of cells analyzed.
Coincidental expression of murine (mu) GAPDH mRNA and PCNA protein in several nude mouse implant samples most probably reﬂects the
presence of murine cells proliferating in the residual capsule surrounding in vivo implants.inﬁltration limited to the periphery [Fig. 3(F)]. Interestingly, an
w100 mm wide zone immediately adjacent to the capsule
was devoid of chondrocytes [Fig. 3(F)]. Chitosan scaffold
was still visible in semithin plastic sections after 7e9 weeks
[Fig. 3(C,E), open arrow]. Compared to day 19 in vitro
chitosan cultured samples, in vivo implants with chondro-
cytes had slightly lower average GAG content, but higher
equilibrium stiffness, comparable ﬁbril modulus, and re-
duced permeability (Table I). Implants with no cells were
friable and unsuitable for mechanical testing. As seen
previously in several studies, mechanical properties of these
in vitro and in vivo constructs remain signiﬁcantly inferior to
those of native tissue (P! 0.05, Table I).
LIVE RABBIT ARTICULAR DEFECT RESIDENCY
When polymerized within ex vivo cartilage defects in pig
or rabbit joints, the chitosan gel adhered strongly to bone
and cartilage after articulation (unpublished results). To test
the manner in which the in situ-gelling chitosan implant
would reside in live articular defects, the chitosan cell
carrier solution without cells was loaded into an osteochon-
dral defect, or into a shallow, but full-thickness chondral
defect in living rabbit joints. The gel was delivered to a3-mm-diameter, 3- to 5-mm-deep, bleeding defect in the
femoral-patellar groove of four, 4-month male rabbits, and
permitted to reside there for 1 day (nZ 1), or 7e8 days
(nZ 3) in vivo. The contralateral knee received an identical
defect with no implant. The gel was also delivered to an
osteochondral patellar defect (nZ 1) and allowed to heal
for 1 day. At the time of surgery, excessive bleeding from
the drill hole in several joints washed the liquid chitosan out
of the defect, requiring a second or third injection before the
gel was able to visibly solidify in the bleeding defect. The
chitosan liquid appeared to be mildly hemostatic, in support
of previous observations43. No effort was made to
immobilize the joint post-surgery.
At 1 day post-surgery, control defects contained a blood
clot packed with red blood cells [Fig. 4(A,C)], while defects
with chitosan gel at 1 day contained variably shaped
implant with blood clot covering the surface and also
mingling with the base of the implant [Fig. 4(B,D)]. At 1
week post-surgery, the control defect contained a red tissue
[Fig. 4(E)] which consisted in highly vascularized granula-
tion tissue [Fig. 4(G,I,K)]. At 1 week post-implantation, all
three defects with a chitosan gel implant were ﬁlled with an
off-white tissue [Fig. 4(F)] that contained variable amounts
of chitosan gel [Fig. 4(H)] covered with a layer of ﬁbrin
324 C. D. Hoemann et al.: Chitosan-based cell-delivery vehicleTable I
Biochemical and mechanical properties of hydrogel cultures, and hydrogel injected implants with or without newborn calf primary
chondrocytes, compared to native calf and adult bovine cartilage. Sample discs, with or without cells, were weighed and frozen and submitted
to biochemical analysis for DNA (cell density), GAG, and collagen content. Additional hydrogel samples, never frozen, were submitted to
unconfined compression tests to determine the biomechanical parameters Em, Ef, and k. MANOVA showed a significant effect of scaffold
(agarose vs chitosan) and day of culture for all dependent outcomes shown in this table (P! 0.05) with the exception of the effect of scaffold
on collagen concentration. Cartilage mechanical properties in unconfined compression have been previously reported11,53
Hydrogel: in vitro culture
Agarose Chitosan gel
NC CCells NC CCells
Days cultured 0 26 0 14 20 0 39 0 14 20
Cell density
(106 cells/g; nZ 4)
0 0 10.8G 0.2 13.4G 1.9 16.4G 3.0 0 0 11.7G 2.0 21.6G 1.7 23.2G 1.8
GAG
(mg/mg tissue; nZ 8)
0 0 0 11.7G 1.8 15.9G 2.4 0 0 0 9.4G 0.9 11.4G 1.5
% Collagen
(mg/mg wt; nZ 4)
0 0 0 0.39G 0.05 1.00G 0.02 0 0 0 0.32G 0.03 0.97G 0.06
Wet weight
(mg; nZ 12)
59G 6 63G3 57G 3 62G 4 63G 3 30G 6 31G4 35G 7 45G 6 43G 6
Days cultured/
implanted
5 20 5 14 20 4 19 4 13 19
Sample number nZ 2 nZ 2 nZ 3 nZ 3 nZ 3 nZ 2 nZ 2 nZ 3 nZ 3 nZ 4
Em, equilibrium
modulus, kPa
7.1a1 2.8b1 6.2G 0.5 17.6G 1.3 28.1G 5.0 1.5c1 1.5d1 1.3G 0.1 8.4G 0.7 11.6G 1.3
k, permeability,
1015 m4/N-s
220a2 180b2 45G 2 22G 1 15G 2 8958c2 13,979d2 1324G 437 137G 21 118G 6
Ef, ﬁbril
modulus, kPa
114a3 166b3 364G 19 610G 10 880G 11 85c3 43d3 36G 18 196G 5 241G 11
Hydrogel: in vivo chitosan implants
NC CCells Cartilage
Calf Adult
Days implanted 48 63 21 48 63 14 days
Sample number nZ 1 nZ 3 nZ 2 nZ 3 nZ 3 nZ 4 nZ 4
Cell density (106 cells/g) – – – – – 65G 4* 30G 4*
GAG (mg/mg tissue) 1.5 1.2G 0.6 4.5e1 5.9G 3.6 7.4G 2.2 55G 5* 44G 13*
% Collagen (mg/mg wt) – – – – – 14.6G 1.8** 16.5G 2.7**
Days implanted 21 48# 63# 14 days
Sample number nZ 1 nZ 1 nZ 1
Em, equilibrium
modulus, kPa
13.9 17.7 12.7 470ˆ 510x
k, permeability, 1015 m4/N-s 77 33 43 3.5ˆ 0.87x
Ef, ﬁbril
modulus, kPa
148 300 268 – 13,600x
Data represented as meanG SD for all samples n R 3. Range of values for samples with nZ 2: a1) 5.5e8.6; a2) 198e243; a3) 113e116;
b1) 2.7e3.0; b2) 171e188; b3) 154e177; c1) 1.4e1.5; c2) 8486e9430; c3) 77e93; d1) 1.4e1.6; d2) 12,452e15,506; d3) 40e46; e1) 4.3e4.6.
Symbols: –Z not done; NCZ no cells. # The same samples were analyzed in Figs. 2 and 3; * from35; ** from35 except that
collagen:hydroxyproline conversion factorZ 7.6, instead of 8.3; ˆ from Ref.11 (Table 2); x from Ref.53 (Fig. 3). All biochemical values given per
wet weight.[Fig. 4(N)]. At 1 week, some cellular inﬁltration into the
chitosan gel was observed [Fig. 4(L), black arrowhead]. A
thick granular repair tissue containing cell debris, neutro-
phils, and ﬁbroblasts surrounded the chitosan implant
[Fig. 4(J,L,M)]. A loose vascular tissue was detected
peripheral to the granulation tissue [Fig. 4(M)]. In contrast
with the subcutaneous chitosan implants, a ﬁbrous capsule
was absent. Histology of osteochondral defects allowed to
heal for up to 1 month (data not shown) suggested that the
cross-linked chitosan gel implant inhibited new bone
formation.
Chitosan gel was also injected into shallow, cartilage-only
defects. In vivo retention of the chitosan matrix wasassessed in a 4! 3 mm2, full-thickness chondral defect of
the patella in a 7-month-old male rabbit [Fig. 5(A)]. The
depth of such a defect in an adult rabbit is around 0.3 mm.
Liquid gel was injected into the defect, allowed to solidify for
5e10 min [Fig. 5(B)], and the knee joint was sutured. The
rabbit was permitted unrestrained motion and load-bearing
for 24 h, after which the patella was dissected, and
processed for histology. In toluidine blue-stained LR White
sections, most of the polymer that ﬁlled the defect was
retained. The gel was partly adhering to bone, and partly
adhering to clotted blood present at the edge of the defect
[Fig. 5(C,D)]. Some neutrophils were present on the surface
of the chitosan gel (data not shown). Similar chitosan gel
325Osteoarthritis and Cartilage Vol. 13, No. 4Fig. 3. Cartilage nodule formation after delivery of chondrocytes, using the injectable, in situ-gelling chitosan-based cell-delivery vehicle.
Hundred microliters of chitosan gel carrying 2 million chondrocytes was injected subcutaneously in nude mice. A) Macroscopic appearance of
a nude mouse carrying chitosan/chondrocyte implants (arrows) 48 days after injection. Appearance of dissected implants together with
a toluidine blue-stained section of the implant showing densely stained, GAG-rich extracellular matrix surrounding chondrocytes at day 48 (B,
C) and day 63 (D, E). The capsular edge of in vivo implants with (F, day 48) or without (G, day 63) chondrocytes showing variable inﬁltration of
murine host cells (arrowheads) and blood vessels (black arrows). Chitosan gel was still present in implants at 7 (C) or 9 (E) weeks (open
arrows).residency in a trochlear chondral-only defect was observed
after 1 day of unrestricted load-bearing (data not shown).
These results demonstrated the retention of chitosan gel
delivered to chondral defects during which time the
experimental animal was allowed unrestricted motion and
full load-bearing for 1 day.
Discussion
A recently developed, injectable and autogelling chito-
san-based cell carrier was studied to determine whether
primary chondrocytes can be effectively delivered using this
carrier, and whether the carrier can adhere and reside indefects of living animals. From the studies presented here,
it was determined that the chitosan self-gelling solution can
1) preserve chondrocyte viability and phenotype after
injection and solidiﬁcation, 2) serve as a scaffolding to help
build tissue with mechanical properties, and 3) reside in
articular defects in live animal joints for at least 1 week after
implantation. These observations suggest the unique
potential of this system for cell-based tissue repair.
Chitosaneglycerol phosphate solutions gel by an endo-
thermal mechanism33,44. It has subsequently been discov-
ered that the hydroxyethyl cellulose, originally used as
a bulking agent, harbors a bifunctional cross-linker that also
participates in the gelation mechanism without compromis-
ing cell viability (unpublished data, in preparation). Previous
326 C. D. Hoemann et al.: Chitosan-based cell-delivery vehicleFig. 4. In vivo delivery, retention of chitosan gel, and inﬂammatory response in example w3 mm deep osteochondral defects in 4-month-old
NZW rabbits. Osteochondral holes 3 mm diameter and w3 mm deep were drilled into the femoral-patellar groove (AeN) with one control
defect allowed to bleed (A,C, E, G, I, K) and the other defect loaded with chitosan gel (B, D, F, H, J, LeN). After 1 day (AeD) or 8 days (EeN)
of normal load-bearing, the joints were recovered and processed for histology. Control defects at 1 day were ﬁlled with a blood clot (A, C).
Control defects at 8 days were ﬁlled with a red (E) vascular granulation tissue (G, I, K), as previously seen52. Chitosan gel implant of variable
shape (B, arrows) was retained in osteochondral defects at 1 day. Chitosan gel was covered with a blood clot at 1 day (D) and a layer of ﬁbrin
at 8 days (N). Defects with chitosan gel at 8 days were ﬁlled with an off-white tissue (F). Cell-mediated degradation of the chitosan implant
(open arrow in H, J) was seen at the implant-granular tissue interface (L, M). Loose vascular tissue containing neutrophils (M, black
arrowhead) was seen adjacent to the granulation tissue surrounding the chitosan. The Growth Plate (Gr Pl) is visible at the base of section (H).work has shown that chondrocytes cangrowon the surface of
chitosan ﬁlms45 and continue to produce cartilage-speciﬁc
molecules. Collective results presented here further show
that chondrocytes can be homogenously encapsulated at
high density within an injectable chitosan hydrogel and
develop mechanical properties over a relatively short in vitro
culture period. Alginate liquid hydrogel has been previously
used to deliver allogeneic chondrocytes to rabbit osteochon-
dral defects46, although chitosan’s known blood compatibil-
ity, mucoadhesivity, and wound-healing properties47 may
prove beneﬁcial compared to other carriers. To our knowl-
edge, the chitosaneglycerol phosphate hydrogel described
here is the only cell-compatible, injectable, in situ-gelling
cell-delivery system shown to adhere to and reside
within full-thickness, chondral articular defects after load-
bearing.
Newborn bovine primary articular chondrocytes in vitro
gave rise to comparable though not identical tissues
when seeded and cultured in 2% agarose11 (Table I), in
1.3% chitosan gels (Table I), and in other scaffolding
materials when grown under static conditions16,48. Newborn
primary chondrocytes appear to have an intrinsic syntheticcapability to deposit matrix, with optimal accumulation in
agarose11 (Table I), near 1 ng GAG per chondrocyte after
a 2e6 week culture period. Our 3-week chitosan cultures
yielded 0.5 ng GAG per chondrocyte at 2e3 weeks. The
higher GAG/cell for agarose could be attributed to its
smaller pore size, allowing greater retention of proteogly-
can. In addition, a lower GAG/cell for chitosan could have
been partly due to the varying presence of a layer of
ﬁbroblast-like cells growing on the matrix surface being
about two cell layers thick for agarose11, vs over ﬁve cell
layers thick at the eroding chitosan gel surface [Fig. 1(H)].
The type I collagen mRNA detected in both agarose and
chitosan cell-laden constructs may have originated from
these ﬁbroblast-like cell layers. Such in vitro de-differenti-
ation at the construct surface has been seen for other
biodegradable scaffoldings such as ﬁbrin49 and PGA50. In
vitro artifacts of surface proliferation, giving rise to cells that
either produce little chondrocyte matrix, or that perhaps
secrete catabolic proteases, could thus partially skew the
global properties of in vitro constructs. It has been
suggested that perfusion or agitation of the cultures could
remove these catabolic factors48,50.
327Osteoarthritis and Cartilage Vol. 13, No. 4Fig. 5. In vivo delivery and retention of chitosan gel in anw0.3 mm deep full-thickness chondral-only defect of an adult NZW rabbit patella (A).
Liquid chitosan gel was injected into to the 4! 3 mm2 full-thickness chondral defect (B). The patella was recovered after 24 h of normal load-
bearing and processed for histology. Toludine blue-stained sections show gel retention and adherence, even after load-bearing to subchondral
bone (arrows in C, D), calciﬁed cartilage (open arrows in C, D) and adjacent articular cartilage (arrowheads in C, D).The mechanical properties measured in chondrocyte-
seeded chitosan gels could be almost wholly attributed to
cell-produced matrix, given the initial weak chitosan gel
stiffness, high porosity, and overt loss of mechanical
strength by constructs without cells over time (Table I).
Although chitosanecell mechanical properties of the mouse
implants appear weaker than those of previous studies19,51
it is important to note that these previous studies employed
an w2.5! higher cell density, longer culture times (8e30
weeks) and also performed conﬁned rather than unconﬁned
compression, all of which could lead to higher apparent
equilibrium moduli. Unconﬁned compression tests reveal
both tensile properties (Ef) and compressive properties
(Em), while only compressive properties can be obtained
from conﬁned compression.
Differences were observed between the inﬂammatory
response to the chitosan gel in subcutaneous implants and
osteochondral defects, potentially due to differential vascu-
lar involvement. Although the chitosan gel adhered well to
ex vivo cartilage and bone, in vivo subchondral defects bled
in such a manner that direct and complete bonding of the
gel with bone was prohibited. Moreover, uncontrolled
mixing of liquid chitosan with subchondral blood resulted
in implants with a variable shape. In contrast, subcutaneous
chitosan implants, which induced no bleeding after in-
jection, were enveloped by a ﬁbrous capsule populated by
a thin layer of neutrophils. The chitosan implant in
osteochondral defects after 1 week was interfaced witha much thicker layer of granulation tissue containing
neutrophils, compared to subcutaneous implants, with no
ﬁbrous capsule formation. Given that an w100 mm zone
adjacent to the nude mouse capsule was noticeably devoid
of chondrocytes, it is possible that the more proliﬁc
osteochondral granulation tissue could have a detrimental
effect on transplant cell viability or phenotype. Collectively,
these observations indicate that scaffold properties seen in
subcutaneous implants or in vitro culture will not necessarily
predict scaffold integration, degradation or inﬂammatory
responses in full-thickness articular cartilage or osteochon-
dral defects. Since implantation of the cross-linked chitosan
cell carrier alone appeared to inhibit bone regeneration in
osteochondral defects, this indicates that the use of this
chitosan gel to repair osteochondral defects could addition-
ally require the delivery of bone-forming cells or factors.
Our data in living animal defects show that the chitosan
gel can reside at least 1 day in a full-thickness chondral
defect, and for at least 1 week in a mobile osteochondral
defect. It is uncertain whether this time frame would be
sufﬁcient to initiate tissue repair by delivered cells. Cartilage
repair therapies using this chitosan hydrogel will additionally
require protection of the initially mechanically fragile implant
from high shear forces. Using the chitosan gel described
here in humans, with controlled post-operative mobility and
an appropriate cell source or growth-factor/cell combination,
delivered cells could gradually produce a viable and
mechanically stable repair tissue at the defect site and
328 C. D. Hoemann et al.: Chitosan-based cell-delivery vehiclethereby contribute to cell-based arthroscopic treatments for
lesions of the articular cartilage.
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